Serum adiponectin and renal dysfunction in men with type 2 diabetes

Diabetes Care

Volumn 30, Issue 2, 2007, Pages 239-244

  Lin, Julie ^a   Hu, Frank B ^a,b   Curhan, Gary ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; LIPID;

ADULT; AGED; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; RACE DIFFERENCE; RISK FACTOR; SEX RATIO;

ADIPONECTIN; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BODY MASS INDEX; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; EXERCISE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; REGRESSION ANALYSIS; SMOKING;

EID: 33846669091     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/dc06-1296     Document Type: Article

References (42)

1. Fattori E, Della Rocca C, Costa P, Giorgio M, Dente B, Pozzi L, Ciliberto G: Development of progressive kidney damage and myeloma kidney in interleukin-6 transgenic mice. Blood 83:2570-2579, 1994
2. Karkar AM, Smith J, Pusey CD: Prevention and treatment of experimental crescentic glomerulonephritis by blocking tumour necrosis factor-alpha. Nephrol Dial Transplant 16:518-524, 2001
3. Erlinger TP, Tarver-Carr ME, Powe NR, Appel LJ, Coresh J, Eberhardt MS, Brancati FL: Leukocytosis, hypoalbuminemia, and the risk for chronic kidney disease in US adults. Am J Kidney Dis 42:256-263, 2003
4. Tonelli M, Sacks F, Pfeffer M, Jhangri GS, Curhan G: Biomarkers of inflammation and progression of chronic kidney disease. Kidney Int 68:237-245, 2005
5. Zinman B, Hanley AJ, Harris SB, Kwan J, Fantus IG: Circulating tumor necrosis factor-alpha concentrations in a native Canadian population with high rates of type 2 diabetes mellitus. J Clin Endocrinol Metab 84:272-278, 1999
6. Nedvidkova J, Smitka K, Kopsky V, Hainer V: Adiponectin, an adipocyte-derived protein. Physiol Res 54:133-140, 2005
7. Becker B, Kronenberg F, Kielstein JT, Haller H, Morath C, Ritz E, Fliser D: Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study. J Am Soc Nephrol 16:1091-1098, 2005
8. Schulze MB, Rimm EB, Shai I, Rifai N, Hu FB: Relationship between adiponectin and glycemic control, blood lipids, and inflammatory markers in men with type 2 diabetes. Diabetes Care 27:1680-1687, 2004
9. Mantzoros CS, Li T, Manson JE, Meigs JB, Hu FB: Circulating adiponectin levels are associated with better glycemic control, more favorable lipid profile, and reduced inflammation in women with type 2 diabetes. J Clin Endocrinol Metab 90:4542-4548, 2005
10. Shetty GK, Economides PA, Horton ES, Mantzoros CS, Veves A: Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care 27:2450-2457, 2004
11. Rothenbacher D, Brenner H, Marz W, Koenig W: Adiponectin, risk of coronary heart disease and correlations with cardiovascular risk markers. Eur Heart J 26:1640-1646, 2005
12. Dunajska K, Milewicz A, Jedrzejuk D, Szymczak J, Kuliczkowski W, Salomon P, Bialy D, Poczatek K, Nowicki P: Plasma adiponectin concentration in relation to severity of coronary atherosclerosis and cardiovascular risk factors in middle-aged men. Endocrine 25:215-221, 2004
13. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB: Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291:1730-1737, 2004
14. Costacou T, Zgibor JC, Evans RW, Otvos J, Lopes-Virella MF, Tracy RP, Orchard TJ: The prospective association between adiponectin and coronary artery disease among individuals with type 1 diabetes: the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetologia 48:41-48, 2005
15. Qi L, Rimm E, Liu S, Rifai N, Hu FB: Dietary glycemic index, glycemic load, cereal fiber, and plasma adiponectin concentration in diabetic men. Diabetes Care 28:1022-1028, 2005
16. Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Cutrupi S, Parlongo S, Malatino LS, Bonanno G, Seminara G, Rapisarda F, Fatuzzo P, Buemi M, Nicocia G, Tanaka S, Ouchi N, Kihara S, Funahashi T, Matsuzawa Y: Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 13:134-141, 2002
17. Lindsay RS, Resnick HE, Zhu J, Tun ML, Howard BV, Zhang Y, Yeh J, Best LG: Adiponectin and coronary heart disease: the Strong Heart Study. Arterioscler Thromb Vasc Biol 25:e15-e16, 2005
18. Lawlor DA, Davey Smith G, Ebrahim S, Thompson C, Sattar N: Plasma adiponectin levels are associated with insulin resistance, but do not predict future risk of coronary heart disease in women. J Clin Endocrinol Metab 90:5677-5683, 2005
19. Statnick MA, Beavers LS, Conner LJ, Corominola H, Johnson D, Hammond CD, Rafaeloff-Phail R, Seng T, Suter TM, Sluka JP, Ravussin E, Gadski RA, Caro JF: Decreased expression of apM1 in omental and subcutaneous adipose tissue of humans with type 2 diabetes. Int J Exp Diabetes Res 1:81-88, 2000
20. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, Kuriyama H, Ouchi N, Maeda K, Nishida M, Kihara S, Sakai N, Nakajima T, Hasegawa K, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Hanafusa T, Matsuzawa Y: Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20:1595-1599, 2000
21. Yenicesu M, Yilmaz MI, Caglar K, Sonmez A, Eyileten T, Kir T, Acikel C, Bingol N, Oguz Y, Ikizler TA, Vural A: Adiponectin level is reduced and inversely correlated with the degree of proteinuria in type 2 diabetic patients. Clin Nephrol 64:12-19, 2005
22. Yu JG, Javorschi S, Hevener AL, Kruszynska YT, Norman RA, Sinha M, Olefsky JM: The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 51:2968-2974, 2002
23. Lindsay RS, Funahashi T, Hanson RL, Matsuzawa Y, Tanaka S, Tataranni PA, Knowler WC, Krakoff J: Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 360:57-58, 2002
24. Lin J, Hu FB, Rimm EB, Rifai N, Curhan GC: The association of serum lipids and inflammatory biomarkers with renal function in men with type II diabetes mellitus. Kidney Int 69:336-342, 2006
25. Rimm EB, Giovannucci EL, Willett WC, Colditz GA, Ascherio A, Rosner B, Stampfer MJ: Prospective study of alcohol consumption and risk of coronary disease in men. Lancet 338:464-468, 1991
26. Hu FB, Leitzmann MF, Stampfer MJ, Colditz GA, Willett WC, Rimm EB: Physical activity and television watching in relation to risk for type 2 diabetes mellitus in men. Arch Intern Med 161:1542-1548, 2001
27. Pischon T, Hotamisligil GS, Rimm EB: Adiponectin: stability in plasma over 36 hours and within-person variation over 1 year. Clin Chem 49:650-652, 2003
28. Tanasescu M, Leitzmann MF, Rimm EB, Hu FB: Physical activity in relation to cardiovascular disease and total mortality among men with type 2 diabetes. Circulation 107:2435-2439, 2003
29. Stevens LA, Coresh J, Greene T, Levey AS: Assessing kidney function-measured and estimated glomerular filtration rate. N Engl J Med 354:2473-2483, 2006
30. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41, 1976
31. Adamczak M, Rzepka E, Chudek J, Wiecek A: Ageing and plasma adiponectin concentration in apparently healthy males and females. Clin Endocrinol (Oxf) 62:114-118, 2005
32. Looker HC, Krakoff J, Funahashi T, Matsuzawa Y, Tanaka S, Nelson RG, Knowler WC, Lindsay RS, Hanson RL: Adiponectin concentrations are influenced by renal function and diabetes duration in Pima Indians with type 2 diabetes. J Clin Endocrinol Metab 89:4010-4017, 2004
33. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y: Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257:79-83, 1999
34. D'Anna R, Baviera G, Corrado F, Giordano D, Di Benedetto A, Jasonni VM: Plasma adiponectin concentration in early pregnancy and subsequent risk of hypertensive disorders. Obstet Gynecol 106:340-344, 2005
35. Bakkaloglu SA, Buyan N, Funahashi T, Pasaoglu H, Elhan AH, Hasanoglu E, Soylemezoglu O: Adiponectin levels and atherosclerotic risk factors in pediatric chronic peritoneal dialysis patients. Perit Dial Int 25:357-361, 2005
36. Guebre-Egziabher F, Bernhard J, Funahashi T, Hadj-Aissa A, Fouque D: Adiponectin in chronic kidney disease is related more to metabolic disturbances than to decline in renal function. Nephrol Dial Transplant 20:129-134, 2005
37. Schalkwijk CG, Chaturvedi N, Schram MT, Fuller JH, Stehouwer CD: Adiponectin is inversely associated with renal function in type 1 diabetic patients. J Clin Endocrinol Metab 91:129-135, 2006
38. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, Nagaretani H, Matsuda M, Komuro R, Ouchi N, Kuriyama H, Hotta K, Nakamura T, Shimomura I, Matsuzawa Y: PPARgamma; ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50:2094-2099, 2001
39. Yang WS, Jeng CY, Wu TJ, Tanaka S, Funahashi T, Matsuzawa Y, Wang JP, Chen CL, Tai TY, Chuang LM: Synthetic peroxisome proliferator-activated receptor-γ agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care 25:376-380, 2002
40. Osei K, Gaillard T, Kaplow J, Bullock M, Schuster D: Effects of rosglitazone on plasma adiponectin, insulin sensitivity, and insulin secretion in high-risk African Americans with impaired glucose tolerance test and type 2 diabetes. Metabolism 53:1552-1557, 2004
41. Shai I, Rimm EB, Schulze MB, Rifai N, Stampfer MJ, Hu FB: Moderate alcohol intake and markers of inflammation and endothelial dysfunction among diabetic men. Diabetologia 47:1760-1767, 2004
42. Iwashima Y, Horio T, Suzuki Y, Kihara S, Rakugi H, Kangawa K, Funahashi T, Ogihara T, Kawano Y: Adiponectin and inflammatory markers in peripheral arterial occlusivedisease.Atherosclerosis 188:384-390, 2006